Pathologic Stage IIIB Cutaneous Melanoma AJCC v8

3

Review clinical trials related to Pathologic Stage IIIB Cutaneous Melanoma AJCC v8. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.

Participants needed: 54
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jun 1, 2026Locations: 1
Eligibility criteria

Provision of written informed consent prior to any study related procedures and... [+10]

Prior malignancy within the previous 2 years except for locally curable cancers... [+23]

Status: Recruiting

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

This study assesses how personal relationships (such as friendships, family relationships, or romantic partners) influence the physical activity (exercise) and well-being of young adult cancer survivors. Researchers also hope to learn how social relationships change after a cancer diagnosis, and how these changes might impact important health behaviors. The information provided may help researchers learn more about better ways to support young cancer patients in the future through interventions that help maintain good social relationships and health levels of physical activity.

Participants needed: 250
Trial details
Age: 18-39Biological sex: AllType: ObservationalSponsor: University of Southern CaliforniaUpdated: May 28, 2026Locations: 2
Eligibility criteria

Diagnosed and/or treated with cancer between ages 18-39 at USC hospitals. [+3]

Diagnosis of blood malignancies such as leukemias (these cancers have divergent... [+2]

Status: Recruiting

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

This trial studies the role of the gut microbiome and effectiveness of a fecal transplant on medication-induced gastrointestinal (GI) complications in patients with melanoma or genitourinary cancer. The gut microbiome (the bacteria and microorganisms that live in the digestive system) may affect whether or not someone develops colitis (inflammation of the intestines) during cancer treatment with immune-checkpoint inhibitor drugs. Studying samples of stool, blood, and tissue from patients with melanoma or genitourinary cancer may help doctors learn more about the effects of treatment on cells, and help doctors understand how well patients respond to treatment. Treatment with fecal transplantation may help to improve diarrhea and colitis symptoms.

Participants needed: 800
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Mar 11, 2026Locations: 1
Eligibility criteria

Diagnosis of any stage melanoma, Non-Small Cell Lung Cancer or genitourinary (GU... [+10]

Age younger than 18 years [+9]